Biotech Values

[DewDiligence]

NVO expands in China:

http://www.novonordisk.com/press/news/news.asp?sShowNewsItemGUID=25fccf0e-50a0-4b71-9ecd-b90ea44a87ee&sShowLanguageCode=en-GB

As the first multinational company to open a research centre in China in 1997, Novo Nordisk now reaffirms its long-term commitment to the country by investing an additional 100 million US dollars to expand its state-of-the-art science facilities in Beijing.

The new 12,000m2 centre will make it possible to increase the number of science employees from the current 130 to 200, with extra space available to accommodate additional future growth.

…The site in Beijing has already contributed significantly to the company’s research and development portfolio in both diabetes and biopharmaceutical target disease areas. The new, expanded facility will enable even stronger contributions from the science team in China across the range of Novo Nordisk’s protein technology, biology and pharmacology research activities.

Remember: 10% of adults in China are diabetic (#msg-48221898).